In Depth 25 Jan 2024
The trends that will shape the biotech industry in 2024
What does 2024 hold for the biotech industry? Delve into the experts’ insight on the biotech trends that will shape 2024.
Mergers & acquisitions
- Latest Posts
News and Trends 8 Jan 2024
Is the biotech industry poised for recovery in 2024?
The past few years have been challenging for the industry but 2024 might be the year marking the biotech recovery.
Weekly Roundup 15 Dec 2023
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
Weekly Roundup 8 Dec 2023
Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
News and Trends 1 Dec 2023
Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered
Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […]
Weekly Roundup 24 Nov 2023
Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA
Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round Chinese company Viva Biotech closed a funding round worth $210 […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 20 Nov 2023
M&As: what’s up with the ADC buying spree?
Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]
Weekly Roundup 10 Nov 2023
Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs
You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […]
In Depth 27 Oct 2023
Big pharma monopolies: major antitrust cases over the past decade
Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby leading to a rise in […]
In Depth 29 Sep 2023
Illumina: DNA giant in troubled waters
A botched acquisition deal and unrest among company investors amid plummeting stocks have plagued Illumina, which was once part of the biotech big leagues that dominated the field of gene sequencing. Now, in fear of losing its ground to other players in the space, it has received a European Commission order to divest Grail, and […]
News and Trends 31 Jul 2023
Biogen acquiring Reata Pharmaceuticals for $7.3B
Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […]
News and Trends 20 Jul 2023
Sosei Heptares hails ‘transformational’ acquisition
Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […]
ADVERTISEMENT
